46-48 Grosvenor Gardens
United Kingdom - Map
Phone: 44 20 7881 0524
Fax: 44 20 7881 1199
Skyepharma PLC, an oral and inhalation drug delivery company, develops, manufactures, and sells oral and inhalation pharmaceutical products. Its marketed products include flutiform and ZYFLO CR for treating asthma; Relvar Ellipta/Breo Ellipta for asthma and COPD; Anoro Ellipta for COPD; Paxil CR for depression treatment; Requip Once-a-day and Madopar DR to treat Parkinsons disease; Triglide for treating lipid disorders; Sular to treat hypertension; Diclofenac-ratiopharm-uno for pain/inflammation; and Lodotra/Rayos to treat rheumatoid arthritis. The companys marketed products also comprise Coruno to treat angina; Xatral OD/Uroxatral for treating BPH (urinary symptoms); Solaraze for actinic keratosis treatment; and EXPAREL, which is used for pain management. Its development pipeline includes SKP-1041, which has completed Phase II clinical trails for sleep maintenance; and SKP-1052, which has completed Phase I clinical trails for use in reducing the risk of nocturnal hypoglycaemia in insulintreated patients. The company also owns a novel inhaled therapy platform. It markets its products through specialty pharmaceutical companies worldwide. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.
|Mr. Peter William Grant ,
Chief Exec. Officer and Exec. Director
|Mr. Andrew Derodra ,
Chief Financial Officer and Exec. Director
|Mr. John Murphy ,
Gen. Counsel and Company Sec.
|Dr. Geraldine Venthoye ,
Exec. VP of Pharmaceutical Devel.
|Dr. Guy Vergnault ,
Exec. VP of Oral Drug Delivery Solutions
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in GBp.|